Oculis Holding AG (OCS) Long-Term Deferred Tax (2023 - 2024)
Oculis Holding AG (OCS) recorded quarterly Long-Term Deferred Tax of $342456.6 in Q4 2024, up 590.39% quarter-over-quarter from $49603.6 in Q4 2023, and up 590.39% on a YoY basis from $49603.6 in Q1 2024.
Oculis Holding AG (OCS) Long-Term Deferred Tax (2023 - 2024) Analysis & Trends
Oculis Holding AG's Long-Term Deferred Tax history runs 2 years deep, the most recent figure standing at $342456.6 for Q4 2024.
- In Q4 2024, Long-Term Deferred Tax rose 590.39% year-over-year to $342456.6; the TTM figure through Dec 2024 stood at $342456.6 (up 590.39% YoY), while the FY2024 annual figure was $342456.6, up 590.39% from the prior year.
- Long-Term Deferred Tax was $342456.6 for Q4 2024 at Oculis Holding AG, up from $49603.6 in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $342456.6 in Q4 2024 to a low of $49603.6 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Oculis Holding AG | 8.23 Bn | 7.92 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 342,456.55 |
| Dec 31, 2023 | 49,603.60 |